Effects of cariprazine on cholesterol, glucose, and weight in patients with schizophrenia: a systematic review and meta-analysis - PubMed
10 hours ago
- #cariprazine
- #metabolic-effects
- #schizophrenia
- Cariprazine is a second-generation antipsychotic approved for treating schizophrenia, bipolar disorder, and major depressive disorder.
- A meta-analysis of studies on cariprazine in schizophrenia patients found a significant difference in weight change compared to placebo, indicating modest weight gain.
- No significant differences were observed in total cholesterol or fasting glucose levels, suggesting a favorable metabolic profile relative to other atypical antipsychotics.